Concert Pharmaceuticals, Inc. (CNCE) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) from a buy rating to a hold rating in a report published on Tuesday.

According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “

CNCE has been the subject of several other reports. Aegis reaffirmed a buy rating and issued a $25.00 target price on shares of Concert Pharmaceuticals in a research report on Monday, June 12th. ValuEngine raised Concert Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, June 23rd. Stifel Nicolaus reaffirmed a buy rating and issued a $30.00 target price (down from $31.00) on shares of Concert Pharmaceuticals in a research report on Monday, July 10th. BidaskClub cut Concert Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, July 12th. Finally, HC Wainwright started coverage on Concert Pharmaceuticals in a research report on Monday, July 24th. They issued a buy rating and a $20.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Concert Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $24.60.

Shares of Concert Pharmaceuticals (NASDAQ:CNCE) opened at 15.19 on Tuesday. Concert Pharmaceuticals has a 12-month low of $7.11 and a 12-month high of $19.11. The company has a 50-day moving average of $14.88 and a 200 day moving average of $14.75. The firm’s market capitalization is $344.62 million.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.04. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.20 million. Concert Pharmaceuticals had a negative net margin of 60,681.70% and a negative return on equity of 61.98%. On average, analysts predict that Concert Pharmaceuticals will post ($2.18) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Concert Pharmaceuticals, Inc. (CNCE) Downgraded to Hold at Zacks Investment Research” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://ledgergazette.com/2017/10/11/concert-pharmaceuticals-inc-cnce-downgraded-to-hold-at-zacks-investment-research.html.

In other news, insider Ryan Lynch sold 3,500 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $14.51, for a total value of $50,785.00. Following the completion of the sale, the insider now directly owns 9,500 shares in the company, valued at $137,845. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 10.10% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Concert Pharmaceuticals by 11.0% in the second quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock worth $10,553,000 after purchasing an additional 74,801 shares during the period. Citadel Advisors LLC acquired a new stake in Concert Pharmaceuticals in the second quarter worth about $6,634,000. Lyon Street Capital LLC increased its position in Concert Pharmaceuticals by 405.5% in the second quarter. Lyon Street Capital LLC now owns 434,752 shares of the biotechnology company’s stock worth $6,065,000 after purchasing an additional 348,741 shares during the period. Driehaus Capital Management LLC acquired a new stake in Concert Pharmaceuticals in the first quarter worth about $7,353,000. Finally, State Street Corp increased its position in Concert Pharmaceuticals by 9.5% in the second quarter. State Street Corp now owns 300,093 shares of the biotechnology company’s stock worth $4,186,000 after purchasing an additional 26,024 shares during the period. Hedge funds and other institutional investors own 61.62% of the company’s stock.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the develop

According to Zacks, “Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. “

CNCE has been the subject of several other reports. Aegis reaffirmed a buy rating and issued a $25.00 target price on shares of Concert Pharmaceuticals in a research report on Monday, June 12th. ValuEngine raised Concert Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, June 23rd. Stifel Nicolaus reaffirmed a buy rating and issued a $30.00 target price (down from $31.00) on shares of Concert Pharmaceuticals in a research report on Monday, July 10th. BidaskClub cut Concert Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, July 12th. Finally, HC Wainwright started coverage on Concert Pharmaceuticals in a research report on Monday, July 24th. They issued a buy rating and a $20.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Concert Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $24.60.

Shares of Concert Pharmaceuticals (NASDAQ:CNCE) opened at 15.19 on Tuesday. Concert Pharmaceuticals has a 12-month low of $7.11 and a 12-month high of $19.11. The company has a 50-day moving average of $14.88 and a 200 day moving average of $14.75. The firm’s market capitalization is $344.62 million.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.04. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.20 million. Concert Pharmaceuticals had a negative net margin of 60,681.70% and a negative return on equity of 61.98%. On average, analysts predict that Concert Pharmaceuticals will post ($2.18) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Concert Pharmaceuticals, Inc. (CNCE) Downgraded to Hold at Zacks Investment Research” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://ledgergazette.com/2017/10/11/concert-pharmaceuticals-inc-cnce-downgraded-to-hold-at-zacks-investment-research.html.

In other news, insider Ryan Lynch sold 3,500 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $14.51, for a total value of $50,785.00. Following the completion of the sale, the insider now directly owns 9,500 shares in the company, valued at $137,845. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 10.10% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Concert Pharmaceuticals by 11.0% in the second quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock worth $10,553,000 after purchasing an additional 74,801 shares during the period. Citadel Advisors LLC acquired a new stake in Concert Pharmaceuticals in the second quarter worth about $6,634,000. Lyon Street Capital LLC increased its position in Concert Pharmaceuticals by 405.5% in the second quarter. Lyon Street Capital LLC now owns 434,752 shares of the biotechnology company’s stock worth $6,065,000 after purchasing an additional 348,741 shares during the period. Driehaus Capital Management LLC acquired a new stake in Concert Pharmaceuticals in the first quarter worth about $7,353,000. Finally, State Street Corp increased its position in Concert Pharmaceuticals by 9.5% in the second quarter. State Street Corp now owns 300,093 shares of the biotechnology company’s stock worth $4,186,000 after purchasing an additional 26,024 shares during the period. Hedge funds and other institutional investors own 61.62% of the company’s stock.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply